Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?
about
Biomarkers and surrogate endpointsAsian strategy for stroke prevention in atrial fibrillationComparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert systemCost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillationUse of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.Relationship between the Occurrence of Thromboembolism and INR Measurement Interval in Low Intensity Anticoagulation after Aortic Mechanical Valve ReplacementManagement of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial.Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese populationAnticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda.Ethnic differences in cardiovascular drug response: potential contribution of pharmacogeneticsNovel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacementThe pharmacogenetics of the response to warfarin in Chinese.INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.Drug Treatment of Venous Thromboembolism in the Elderly.Cerebral stroke after valvular surgery in young patients: case studies.Mitral valve replacement in a dialysis-dependent patient.Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan.Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Today's science, tomorrow's medicines.D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial.Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement.Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia.Atrial fibrillation
P2860
Q24678760-F2BBD1C1-30B3-4D24-9ED8-F030D500A2F0Q28072723-E79449CD-E77B-4491-BB65-96D8E1BFAF7DQ33912263-51A1F1E4-4962-4D38-9591-60382456718EQ34321590-5CF1B9A4-2955-49D9-82E1-7AECDDB9B56BQ34351204-6C228D7A-8B3B-47BF-ABE9-61F6716054C2Q34633608-2CDCC4CA-A130-4138-9287-3A54B7A16E8FQ35644607-EC0FC43F-A09A-4F95-8464-0CDAA05D3318Q35827850-ABBC3760-0FF2-42A9-BCBD-9F13DCD61E28Q36611995-D0A02039-5633-47A2-92F9-B8C2D714DF39Q36776490-E7CADAF5-3572-4710-9E4B-BC48A928B1E3Q37042030-96E40932-377B-4FE7-A613-DCC1FFB4E45BQ37276490-98DA8E1A-B179-4DB5-AE30-E4D3EEC3FF70Q37595758-2BEC43D6-2FF6-44A2-8642-7C06D0C4D0ECQ37606335-363B4969-A146-46B7-8C4A-55731E109F8CQ37948863-D3451FFA-A9BA-4E12-9965-D88567CC8FB0Q38525931-D3C40FAC-1F92-45EE-B889-1F4F4B749908Q38851927-B325F257-DD50-423C-8DFF-C00BFE922CABQ39033493-DB34135D-1CC4-44CF-B08D-D528174CC32AQ40527689-A3BEFB8E-1D52-4774-99E5-334C4BFD724BQ40731226-128144E2-028F-4048-BB5B-82E1CAE413CFQ41763962-FA86D8DF-79FA-43AA-A417-04CD913F6CF7Q43654143-7245C69A-CEA2-46BA-9A34-32FB1537260DQ45942815-7682D9A4-513F-475E-8C1B-CA07215D8BFDQ46154777-F8D98339-F882-450D-944D-80D421759EB3Q48314582-36908C03-A2C1-4B8C-B547-8DC3993B1861Q48690350-2FAE6B75-B008-4717-B2C5-079EF69CD668Q50950032-DB17B2B9-9E97-4FE4-9AE0-166E3FD03300Q53080068-079DFB99-19D7-4211-8F27-F49FAAEA3264Q53099910-1F609CE0-239B-4743-A125-20300F6B600CQ56607936-28EFEC23-0475-43B1-9D56-AA4478B81B37
P2860
Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@ast
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@en
type
label
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@ast
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@en
prefLabel
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@ast
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@en
P2860
P1476
Is INR between 2.0 and 3.0 the ...... ate-intensity anticoagulation?
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.2005.02361.X
P407
P577
2005-05-01T00:00:00Z